RVTY · Revvity, Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 4, 2026TL;DR. Revvity beat Q2 expectations and raised full-year guidance, now expecting 4-5% pro forma organic growth (up from 3-4%) and adjusted EPS of $5.30-$5.40 (up $0.10), driven by accelerating AI-related demand and strong Diagnostics, while entering a definitive agreement to divest its China Immunodiagnostics business by end of 2027.
- + Raised full-year pro forma organic growth outlook to 4-5% from prior 3-4%.
- + Raised full-year pro forma adjusted EPS outlook to $5.30-$5.40, up $0.10 from prior guidance.
- + High-content screening (Opera Phoenix OptIQ) saw double-digit order growth with backlog outpacing near-term production capacity, signaling strong AI-driven demand.
- + Q2 pro forma adjusted operating margin of 29.3% exceeded the 27% guidance even excluding $16M of tariff refunds, with 117% cash flow conversion of adjusted net income.
- − Pharma and biotech customer sales declined mid-single digits in Q2 (excluding software, only low single-digit growth) due to difficult prior-year comps.
- − Reproductive health is expected to decelerate sharply to low-to-mid single digit organic growth in H2 from mid-teens in H1, due to Genomics England comps and heavier H1 instrument placements.
- − Management reinvested roughly half of the Q2 tariff refund benefit, muting full-year EPS upside relative to gross tariff benefit.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RVTY
this stock
Revvity, Inc.
|
$16.01B | +48.4% | -13.5% | 68.6 | 5.7% |
|
TMO
Thermo Fisher Scientific Inc.
|
$240.87B | +13.7% | +14.5% | 35.0 | 1.5% |
|
DHR
Danaher Corp /De/
|
$147.37B | -5.7% | +8.5% | 37.2 | 1.4% |
|
NTRA
Natera, Inc.
|
$53.25B | +61.8% | -2.8% | — | 3.8% |
|
IQV
Iqvia Holdings Inc.
|
$44.71B | +19.7% | +41.6% | 33.3 | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RVTY | +11.8% | +15.1% | +69.4% | +11.6% | +48.4% |
| SPY | +1.7% | +1.0% | +22.4% | +0.8% | +13.4% |
| vs SPY | +10.1% | +14.1% | +47.0% | +10.8% | +35.0% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.